Did Cardinal Health beat or miss consensus estimates last quarter?

What were the key takeaways from Cardinal Health’s earnings call?

What is the revenue and EPS growth rate for Cardinal Health year over year?

What is Cardinal Health's latest dividend and current dividend yield?

What does Cardinal Health do and what are its main business segments?

What guidance did Cardinal Health's management provide for the next earnings period?

What factors drove the changes in Cardinal Health's revenue and profit?

What is the market's earnings forecast for Cardinal Health next quarter?

- **Record Q1 Performance**: 37% operating earnings growth and 36% EPS growth, driven by 22% revenue increase to $64 billion.
- **Strategic Acquisitions**: Solaris Health acquisition to close shortly, adding $0.05 EPS accretion. ADS integration ahead of schedule, with 51% revenue growth in at-Home Solutions.
- **Updated Guidance**: Full-year EPS raised to $9.65-$9.85 (17%-20% growth), free cash flow to $3-$3.5 billion.
- **Segment Strength**: Pharmaceutical and Specialty Solutions up 23%, Nuclear and Precision Health theranostics up 30%, OptiFreight Logistics up 21%.
- **Infrastructure Investment**: New distribution centers and automation driving efficiency. Cardinal Health-branded products grow 6% in GMPD.
- **Policy Resilience**: Business model adapts to regulatory changes, with focus on service quality and utilization trends.

**【CEO Summary Section】**
- Cardinal Health reported a strong start to FY26 with double-digit profit growth across all 5 operating segments. The Pharmaceutical and Specialty Solutions segment led growth, driven by robust demand and expansion into specialty care. The acquisition of Solaris Health, the largest urology MSO, is expected to close shortly, enhancing the Specialty Alliance platform. Integration of ADS into at-Home Solutions is progressing well, with synergies realized earlier than anticipated. Investments in infrastructure, including new distribution centers and automation, are supporting operational efficiency.

**【CFO Financial Commentary】**
- Q1 FY26 results showed 37% operating earnings growth and 36% EPS growth, driven by strong demand and strategic investments. Total revenue increased 22% to $64 billion, with Pharmaceutical and Specialty Solutions contributing 23% growth. Solaris Health is expected to add $0.05 EPS accretion for the partial year. Full-year EPS guidance was raised to $9.65-$9.85, reflecting 17%-20% growth. Adjusted free cash flow guidance was increased to $3-$3.5 billion. The company generated $1.3 billion in free cash flow, with $500 million returned to shareholders through dividends and share buybacks.

**【Q&A Highlights】**
- **Policy Impact**: Executives expressed confidence in the business model's resilience amid regulatory changes, noting strong utilization trends and investments in service quality. 
- **Integration Progress**: ADS integration is ahead of schedule, with minimal capacity utilization and focus on back-office operations. Solaris Health's distribution business is expected to onboard later in FY26.
- **Segment Growth**: At-Home Solutions delivered 51% revenue growth, Nuclear and Precision Health Solutions saw 17% growth (30% in theranostics), and OptiFreight Logistics grew 21%. GMPD's Cardinal Health-branded products grew 6%, driven by clinically differentiated products.
- **Biosimilars**: The company views biosimilars as a long-term opportunity, with potential regulatory support to reduce barriers to entry.

CAH

CAH fundamentals

You can ask Aime